Navigation Links
Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology
Date:1/25/2010

PLEASANTON, Calif., Jan. 25 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support (MCS) therapies to save, support and restore failing hearts, said today that it has acquired an innovative catheter pump technology that it plans to use in the development of a minimally invasive, acute cardiac axial flow pump that can be delivered percutaneously in the cardiac catheterization lab and operating room.

Thoratec is paying a cash purchase price of $8.5 million to Getinge AB (Stockholm: GETIB) for the technology, which will be recorded as an expense in the first quarter of 2010.  The company expects to incur incremental development costs of up to $3 million in 2010.  Overall financial guidance for 2010 will be provided during the upcoming fourth quarter earnings call.

"This technology represents a compelling opportunity for Thoratec as we broaden our leadership position in MCS therapies. There is an unmet need for a device that can provide fast and minimally invasive acute cardiac support for hemodynamically unstable acute myocardial infarction, high risk percutaneous coronary intervention and post-cardiotomy patients. Given its potential ability to provide greater flow at a smaller size than other existing devices, we believe this technology offers the potential to be the basis for a breakthrough offering in this very significant market," said Gary F. Burbach, president and chief executive officer of Thoratec.

"We will be using our proven competencies in MCS while adding to our research and development team to advance this product developme
'/>"/>

SOURCE Thoratec Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Thoratec Schedules Fiscal 2009 Year-End Conference Call, Webcast
2. Thoratec Announces FDA Approval of HeartMate II(R) for Destination Therapy
3. Thoratec Presentation at Piper Jaffray Conference to be Webcast
4. Thoratec Investor Meeting to Review HeartMate II (R) Destination Therapy Trial Data to Be Webcast
5. Thoratec Presentation at Canaccord Adams Conference to be Webcast
6. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
7. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
8. Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation
9. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
10. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
11. Warner Chilcott Announces 2010 Financial Guidance Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... , SWARTZ CREEK, Mich., Nov. 17 Diplomat Specialty ... Bernardino, CA . Diplomat has 6 additional locations in ... contracts with managed care organizations in California will potentially impact ... Managed Care. "Our new San Bernardino location is an important ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 17 ... announced updated clinical data from its randomized, controlled Phase ... cancer (CRC). The updated results indicated that picoplatin, ... and leucovorin in the FOLPI regimen, has comparable efficacy ...
Cached Medicine Technology:Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 5
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions of ... immune response to infection with malaria parasites that may ... and illness and partially control the growth of malaria ... develop future interventions that prevent or mitigate the disease ... 200 million cases of malaria occur worldwide, resulting in ...
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2
... investigational device that specifically targets rapidly growing cancer cells ... (TTFields), has found that it more than doubled the ... common and aggressive type of malignant brain tumor. ... to disrupt tumor growth by interfering with cell division ...
... survey of DNA samples from nearly 50,000 women, half of ... mutation that holds 60 per cent increased risk of breast ... of Cambridge says that the gene mutation was observed in ... ,The researchers say that the newly identified gene variant, in ...
... has announced a 90 percent reduction in the price of ... rising number of deaths caused by them. ... 3,500 "people's pharmacies," where the government offers subsidized medicines. ... Catholic Church and Lula's government over abortion. ,During ...
... Pharmaceuticals Inc. has received final approval from the U.S. ... Abbreviated New Drug Application (ANDA) for Fluoxetine Capsules USP, ... version of Eli Lilly and Company's Prozac(R) Capsules. Fluoxetine ... the 12 months ending March 31, 2007, for the ...
... high staffing standards for elder care in nursing homes are ... nurses to prevent serious safety violations, according to a ... Nursing. ,The majority of the nation's elderly and ... well below national recommendations for safe care, the study found. ...
... analysing climate simulations we can see there are changes in ... variability',said CSIRO oceanographer Dr Gael Alory. ,'These ... heat structure of the atmosphere and have led to a ... around two degrees celsius. ,'At the same time, ...
Cached Medicine News:Health News:Device That Targets Brain Cancer Shows Promising Results 2Health News:Researchers Identify the Gene Mutation That Raises Breast Cancer Risk 2Health News:Policy Changes Have Direct Effect on Nursing Home Care 2Health News:Policy Changes Have Direct Effect on Nursing Home Care 3Health News:Climate Change Signal Detected in the Indian Ocean 2
Inquire...
... A fast, reliable and accurate immunoassay ... and plasma. , ,The fully automated Elecsys ... failure in symptomatic patients. NT-proBNP levels also ... allow the assessment of prognosis. In addition, ...
... there is a more efficient way ... fully portable battery operated patient warming ... surgical teams with a compact and ... the entire surgical process. Its unique ...
... system consists of our compact and ... blankets for use with patients of ... Blankets are available for intra and ... sizes and a sterile cardiac blanket ...
Medicine Products: